Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:NVAX NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.24-2.6%$10.48$7.21▼$22.37$1.96B0.836.95 million shs2.97 million shsNVAXNovavax$9.21+2.6%$8.85$6.13▼$11.97$1.48B2.375.47 million shs4.42 million shsTARAProtara Therapeutics$4.92-1.0%$5.16$2.77▼$7.82$279.33M1.53741,360 shs1.13 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.60%-0.36%-24.75%-48.82%-59.05%NVAXNovavax+2.56%+1.66%+8.99%+0.11%+29.54%TARAProtara Therapeutics-1.01%-3.53%-9.06%-28.07%+51.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.24-2.6%$10.48$7.21▼$22.37$1.96B0.836.95 million shs2.97 million shsNVAXNovavax$9.21+2.6%$8.85$6.13▼$11.97$1.48B2.375.47 million shs4.42 million shsTARAProtara Therapeutics$4.92-1.0%$5.16$2.77▼$7.82$279.33M1.53741,360 shs1.13 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.60%-0.36%-24.75%-48.82%-59.05%NVAXNovavax+2.56%+1.66%+8.99%+0.11%+29.54%TARAProtara Therapeutics-1.01%-3.53%-9.06%-28.07%+51.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.40Hold$19.00130.58% UpsideNVAXNovavax 2.10Hold$12.1331.65% UpsideTARAProtara Therapeutics 2.75Moderate Buy$26.25433.54% UpsideCurrent Analyst Ratings BreakdownLatest ADMA, TARA, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026TARAProtara Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$25.00 ➝ $28.005/20/2026TARAProtara Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/20/2026TARAProtara Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026TARAProtara Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $26.005/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/7/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.005/7/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$24.00 ➝ $20.005/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.004/29/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $27.004/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.74$0.64 per share12.93$1.68 per share4.90NVAXNovavax$1.12B1.35$3.60 per share2.56($0.88) per share-10.47TARAProtara TherapeuticsN/AN/AN/AN/A$3.22 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.127.85N/A32.43%39.98%28.08%8/5/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)TARAProtara Therapeutics-$57.44M-$1.34N/AN/AN/AN/A-38.70%-36.02%7/30/2026 (Estimated)Latest ADMA, TARA, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TARAProtara Therapeutics-$0.36-$0.31+$0.05-$0.31N/AN/A5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million3/10/2026Q4 2025TARAProtara Therapeutics-$0.34-$0.37-$0.03-$0.37N/AN/A2/26/2026Q4 2025NVAXNovavax-$0.66$0.11+$0.77$0.11$90.26 million$136.40 million2/25/2026Q4 2025ADMAADMA Biologics$0.20$0.20N/A$0.20$139.80 million$139.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93NVAXNovavaxN/A2.482.45TARAProtara TherapeuticsN/A15.6915.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%NVAXNovavax53.04%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%NVAXNovavax1.00%TARAProtara Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableNVAXNovavax1,990164.44 million162.79 millionOptionableTARAProtara Therapeutics3056.20 million51.93 millionOptionableADMA, TARA, and NVAX HeadlinesRecent News About These CompaniesFoghorn Therapeutics (FHTX) Receives a Buy from H.C. WainwrightMay 21 at 6:02 PM | theglobeandmail.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 21 at 2:15 AM | americanbankingnews.comProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHAMay 20 at 8:00 AM | globenewswire.comProtara Therapeutics, Inc. $TARA Shares Bought by UBS Group AGMay 20 at 6:38 AM | marketbeat.comProtara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations TranscriptMay 19, 2026 | seekingalpha.comProtara’s cell therapy shows treatment durability in mid-stage NMIBC studyMay 19, 2026 | msn.comProtara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical ProgramMay 18, 2026 | quiverquant.comQProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026May 18, 2026 | globenewswire.comLifesci Capital Has Optimistic Outlook of TARA Q2 EarningsMay 18, 2026 | americanbankingnews.comProtara Therapeutics (NASDAQ:TARA) Rating Increased to Sell at Wall Street ZenMay 16, 2026 | americanbankingnews.comProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of ...May 15, 2026 | markets.businessinsider.comProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBCMay 15, 2026 | globenewswire.comProtara Therapeutics (NASDAQ:TARA) Price Target Cut to $26.00 by Analysts at JPMorgan Chase & Co.May 15, 2026 | americanbankingnews.comProtara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateMay 13, 2026 | globenewswire.comProtara Therapeutics (TARA) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comOne Protara Therapeutics Insider Raised Their Stake In The Previous YearMay 4, 2026 | finance.yahoo.comEquities Analysts Offer Predictions for TARA FY2028 EarningsMay 4, 2026 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Price Target Raised to $27.00 at HC WainwrightApril 29, 2026 | marketbeat.comProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...April 28, 2026 | markets.businessinsider.comProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingApril 27, 2026 | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from BrokeragesApril 26, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Broadcom Hits $2 Trillion Market Cap as Google Reveals New AI ChipsBy Leo Miller | April 28, 2026ADMA, TARA, and NVAX Company DescriptionsADMA Biologics NASDAQ:ADMA$8.24 -0.22 (-2.60%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$8.26 +0.02 (+0.19%) As of 05/22/2026 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Novavax NASDAQ:NVAX$9.21 +0.23 (+2.56%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.20 -0.01 (-0.05%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Protara Therapeutics NASDAQ:TARA$4.92 -0.05 (-1.01%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.93 +0.01 (+0.20%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
